| Crude suicide rates (per 100 000 population) WHO | WHO | – |
| Age-standardized suicide rates (per 100 000 population) WHO | WHO | −14.3% |
| Mortality rate attributed to unintentional poisoning (per 100 000 population) WHO | WHO | +25% |
| Premature deaths due to noncommunicable diseases (NCD) as a proportion of all NCD deaths WHO | WHO | +2.3% |
| Age-standardized NCD mortality rate (per 100 000 population) WHO | WHO | +6.1% |
| Total NCD Deaths WHO | WHO | +13.3% |
| Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease WHO | WHO | +4.8% |
| Adult mortality rate (probability of dying between 15 and 60 years per 1000 population) WHO | WHO | −9.6% |
| Number of female leprosy new cases WHO | WHO | +100% |
| New leprosy child case detection rate (less than 15 years of age) per 1 000 000 child population WHO | WHO | 0 |
| Number of non-autochthonous leprosy cases WHO | WHO | +40% |
| New leprosy case detection rate per 1 000 000 population WHO | WHO | −13.4% |
| Leprosy - Number of cases registered for treatment WHO | WHO | −11.6% |
| Leprosy registered prevalence rate per 1 000 000 population WHO | WHO | −12.6% |
| Number of new G2D leprosy cases WHO | WHO | 0% |
| Leprosy - New leprosy cases with G2D rate per 1 000 000 population WHO | WHO | 0% |
| Leprosy - Number of new leprosy cases among children (less than 15 years of age) WHO | WHO | 0 |
| Number of new leprosy cases with G2D among children (less than 15 years of age) WHO | WHO | 0 |
| Number of new leprosy cases WHO | WHO | −12.5% |
| New chronic hepatitis B (HBV) infections (number) WHO | WHO | – |
| Hepatitis - Deaths caused by chronic hepatitis B and C (per 100 000 population) WHO | WHO | – |
| People living with chronic hepatitis B (HBV) (number) WHO | WHO | – |
| Prevalence of chronic hepatitis B (HBV) in the general population (%) WHO | WHO | – |
| New chronic hepatitis C (HCV) infections (number) WHO | WHO | – |
| People living with chronic hepatitis C (HCV) including cured (all ages) (adjusted number) WHO | WHO | +13.1% |
| People living with chronic hepatitis C (HCV) (number) WHO | WHO | – |
| Prevalence of chronic hepatitis C (HCV) ) in the general population (%) WHO | WHO | – |
| Hepatitis - Deaths caused by chronic hepatitis B and C WHO | WHO | – |
| Persons on chronic hepatitis B (HBV) treatment (number) WHO | WHO | – |
| Chronic hepatitis B (HBV) treatment rate as percentage of diagnosed (%) WHO | WHO | – |
| Chronic hepatitis B (HBV) treatment rate as percentage of total infected (%) WHO | WHO | – |
| Persons on chronic hepatitis C (HCV) treatment, cumulative (number) WHO | WHO | – |
| Chronic hepatitis C (HCV) cumulative treatment rate as percentage of total infected, including cured (%) WHO | WHO | – |
| Persons initiated chronic hepatitis C(HCV) treatment (number) WHO | WHO | – |
| Chronic hepatitis C (HCV) treatment rate as percentage of diagnosed (%) WHO | WHO | – |
| Chronic hepatitis B (HBV) infected persons diagnosed (number) WHO | WHO | – |
| Chronic hepatitis B (HBV) diagnosis coverage as a percentage of infected (%) WHO | WHO | – |
| Chronic hepatitis C (HCV) infected persons diagnosed, including cured (number) WHO | WHO | – |
| Chronic hepatitis C (HCV) infected persons diagnosed (number) WHO | WHO | −13.1% |
| Chronic hepatitis C (HCV) diagnosis coverage as percentage of total HCV infected, including cured (%) WHO | WHO | – |
| Pregnant women attending antenatal care, tested for HBsAg (percent) WHO | WHO | +5.2% |
| Pregnant women attending antenatal care, tested positive for HBsAg (percent) WHO | WHO | −0.2 |
| Eligible women attending antenatal care who were treated for HBV WHO | WHO | 0 |
| Life expectancy at birth (years) WHO | WHO | +0.3% |
| Healthy life expectancy (HALE) at birth (years) WHO | WHO | +0.3% |
| Healthy life expectancy (HALE) at age 60 (years) WHO | WHO | −0.6% |
| Life expectancy at age 60 (years) WHO | WHO | +0.9% |
| Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%) WHO | WHO | +1.8% |
| Physical activity policies for activie societies WHO | WHO | −1 |
| Physical activity policies focused on active systems WHO | WHO | +1 |
| Number of imported cases of visceral leishmaniasis reported WHO | WHO | 0 |
| Overweight numbers among children under 5 years of age (thousands), model-based estimates WHO | WHO | +3.1% |
| Overweight prevalence among children under 5 years of age (% weight-for-height >+2 SD), model-based estimates WHO | WHO | +3.7% |
| Stunting numbers among children under 5 years of age (millions), model-based estimates WHO | WHO | −1.1% |
| Stunting prevalence among children under 5 years of age (% height-for-age <-2 SD), model-based estimates WHO | WHO | −0.9% |
| Number of under-five deaths WHO | WHO | −3.2% |
| Under-five mortality rate (probability of dying by age 5 per 1000 live births) WHO | WHO | −2.3% |
| Stillbirth rate (per 1000 total births) WHO | WHO | −1.5% |
| Number of deaths among children ages 5 to 9 years WHO | WHO | −2.5% |
| Mortality rate among children ages 5 to 9 years (per 1000 children aged 5) WHO | WHO | 0% |
| Number of neonatal deaths WHO | WHO | −3.2% |
| Neonatal mortality rate (per 1000 live births) WHO | WHO | −3% |
| Number of deaths among children 5 to 14 years of age WHO | WHO | −2.4% |
| Mortality rate for 5-14 year-olds (probability of dying per 1000 children aged 5-14 years) WHO | WHO | 0% |
| Number of women of reproductive age (aged 15-49 years) with anaemia (thousands) WHO | WHO | +4.5% |
| Number of infant deaths WHO | WHO | −3.1% |
| Infant mortality rate (probability of dying between birth and age 1 per 1000 live births) WHO | WHO | −2.7% |
| Number of deaths among adolescents (10 to 19 years of age) WHO | WHO | −2.2% |
| Adolescent mortality rate (per 1 000 age specific cohort) WHO | WHO | 0% |
| Hepatitis B surface antigen (HBsAg) prevalence (%) WHO | WHO | −50% |
| Estimated number of people (all ages) living with HIV WHO | WHO | +7.7% |
| Number of people dying from HIV-related causes WHO | WHO | 0% |
| Reported number of people receiving antiretroviral therapy WHO | WHO | +8.5% |
| Reported number of children receiving antiretroviral therapy WHO | WHO | +1.6% |
| Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission WHO | WHO | −0.8% |
| Estimated number of pregnant women living with HIV WHO | WHO | −1.3% |
| Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission WHO | WHO | 0% |
| Estimated number of children needing antiretroviral therapy based on WHO methods WHO | WHO | 0% |
| Estimated antiretroviral therapy coverage among children WHO | WHO | +2% |
| Number of new HIV infections WHO | WHO | −2.9% |
| Estimated antiretroviral therapy coverage among people living with HIV (%) WHO | WHO | +3.9% |
| Prevalence of HIV among adults aged 15 to 49 (%) WHO | WHO | 0% |
| New HIV infections (per 1000 uninfected population) WHO | WHO | 0% |
| Childhood cancer survival for lymphoid leukaemia, age-standardized 5-year net survival (%) WHO | WHO | – |
| End-of-life care OECD | OECD | – |
| Healthcare quality and outcomes OECD | OECD | −16.5% |
| Mental healthcare OECD | OECD | – |
| Prescribing in primary care OECD | OECD | – |
| Patient safety OECD | OECD | – |
| International Health Regulations core capacity scores, SPAR version, 2nd edition WHO | WHO | +5% |
| Revenues of healthcare financing schemes OECD | OECD | 0% |
| Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem WHO | WHO | +2% |
| Number of people who received treatment with antibiotics for trachoma WHO | WHO | 0 |
| Reported number of human rabies deaths WHO | WHO | +100% |
| Number of people operated for trachomatous trichiasis WHO | WHO | 0 |
| HPV immunization coverage estimates among primary target cohort (9-14 years old girls) (%) WHO | WHO | +59% |
| Polio (Pol3) immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| Pertussis - number of reported cases WHO | WHO | +1,738.5% |
| Total tetanus - number of reported cases WHO | WHO | −20% |
| Yellow fever - number of reported cases WHO | WHO | +157.9% |
| Rubella - number of reported cases WHO | WHO | 0 |
| Diphtheria - number of reported cases WHO | WHO | 0 |
| Mumps - number of reported cases WHO | WHO | +3.6% |
| Congenital Rubella Syndrome - number of reported cases WHO | WHO | 0 |
| Neonatal tetanus - number of reported cases WHO | WHO | +100% |
| Measles - number of reported cases WHO | WHO | +150% |
| Pneumoccocal conjugate vaccines (PCV3) immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| Rotavirus vaccines completed dose (RotaC) immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| Yellow fever vaccine (YFV) immunization coverage among 1-year olds (%) WHO | WHO | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage by the nationally recommended age (%) WHO | WHO | 0% |
| Hib (Hib3) immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| Inactivated first-dose polio vaccine (IPV1) immunization coverage among 1-year-olds (%) (WUENIC) WHO | WHO | 0% |
| Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| BCG immunization coverage among 1-year-olds (%) WHO | WHO | 0% |
| Diphtheria tetanus toxoid and pertussis first-dose (DTP1) immunization coverage among 1-year-olds (%) (WUENIC) WHO | WHO | 0% |
| Avoidable mortality OECD | OECD | −53.5% |
| Communicable diseases OECD | OECD | −11.9% |
| Injuries OECD | OECD | +6% |
| Infant health: low birthweight OECD | OECD | −2.9% |
| Life expectancy OECD | OECD | −1.9% |
| Maternal and infant mortality OECD | OECD | −2.7% |
| Potential years of life lost OECD | OECD | −6.7% |
| Adopted written national policy on alcohol WHO | WHO | 0 |
| Alcoholic beverage legally defined WHO | WHO | – |
| National legislation to prevent illegal alcohol WHO | WHO | – |
| Standard drink defined WHO | WHO | – |
| National drinking guidelines WHO | WHO | – |
| National legislation to prevent illegal alcohol sales WHO | WHO | – |
| Hospital aggregates OECD | OECD | +31% |
| Consultations OECD | OECD | 0% |
| Diagnostic exams OECD | OECD | – |
| Immunisations OECD | OECD | −8.7% |
| Screening OECD | OECD | – |
| Surgical procedures OECD | OECD | – |
| Waiting times OECD | OECD | – |
| Remuneration of health professionals OECD | OECD | – |
| Generic market OECD | OECD | – |
| Pharmaceutical market OECD | OECD | – |
| Pharmaceutical consumption OECD | OECD | – |
| Pharmaceutical sales OECD | OECD | – |
| Healthcare coverage OECD | OECD | −1.5% |
| Risk factors for health OECD | OECD | +4.1% |
| Alcohol consumption OECD | OECD | +4.1% |
| Body weight OECD | OECD | +6.8% |
| Food supply and consumption OECD | OECD | −1.7% |
| Tobacco consumption OECD | OECD | −50% |
| Government monopoly on production WHO | WHO | 0 |
| Government monopoly on retail sales WHO | WHO | 0 |
| Detection of marketing infringements WHO | WHO | – |
| Penalties for marketing infringements WHO | WHO | – |
| Off-premise sales restrictions on days WHO | WHO | 0 |
| Off-premise sales restrictions on hours WHO | WHO | 0 |
| Off-premise sales restrictions on places WHO | WHO | 0% |
| Off-premise sales restrictions on outlet density WHO | WHO | 0 |
| On-premise sales restrictions on days WHO | WHO | 0 |
| On-premise sales restrictions on hours WHO | WHO | 0 |
| On-premise sales restrictions on places WHO | WHO | 0% |
| On-premise sales restrictions on outlet density WHO | WHO | 0 |
| On-premise sales restrictions to intoxicated persons WHO | WHO | – |
| Server training WHO | WHO | – |
| Level of taxation adjusted for inflation WHO | WHO | – |
| Duty paid or excise stamp on alcohol container WHO | WHO | – |
| Number of standard alcoholic drinks displayed on containers WHO | WHO | 0 |
| Alcohol content displayed on containers WHO | WHO | −1 |
| Health warning labels on pregnancy WHO | WHO | −1 |
| Health warning labels on under-age drinking WHO | WHO | −1 |
| Health warning labels on drink-driving WHO | WHO | −1 |
| Health warning labels on alcohol advertising WHO | WHO | – |
| Health warning labels on alcohol containers WHO | WHO | – |
| Legal blood alcohol concentration (BAC) limits WHO | WHO | 0% |
| Age limits off-premise sales WHO | WHO | 0% |
| Random breath testing (RBT) use WHO | WHO | – |
| Penalties for drink driving WHO | WHO | – |
| Sobriety checkpoints WHO | WHO | – |
| Graduated licensing WHO | WHO | – |
| Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), by beverage type WHO | WHO | 0% |
| Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average WHO | WHO | 0% |
| Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol), three-year average WHO | WHO | 0% |
| Alcohol, tourist consumption (in litres of pure alcohol), three-year average WHO | WHO | 0 |
| Alcohol, consumption of pure alcohol by type of beverage (%) WHO | WHO | 0% |
| Cancer survival for those diagnosed with breast cancer, 5-year net survival (%) WHO | WHO | – |
| Number of imported cases of cutaneous leishmaniasis reported WHO | WHO | +9 |
| Number of cases of cutaneous leishmaniasis reported WHO | WHO | +2.3% |
| Household air pollution attributable deaths WHO | WHO | – |
| Household air pollution attributable DALYs WHO | WHO | – |
| Household air pollution attributable DALYs (per 100 000, age-standardized) WHO | WHO | – |
| Household air pollution attributable death rate (per 100 000 population, age-standardized) WHO | WHO | – |
| Ambient air pollution attributable deaths WHO | WHO | – |
| Ambient air pollution attributable death rate (per 100 000 population, age-standardized) WHO | WHO | – |
| Ambient air pollution attributable DALYs WHO | WHO | – |
| Ambient air pollution attributable DALYs (per 100 000 population, age-standardized) WHO | WHO | – |
| Joint effects of air pollution attributable deaths WHO | WHO | – |
| Household and ambient air pollution attributable DALYs (per 100 000 capita, age-standardized) WHO | WHO | – |
| Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized) WHO | WHO | – |
| Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2), three-year average WHO | WHO | 0% |
| Exclusive breastfeeding under six months (in thousands) WHO | WHO | −0.2% |
| Low birth weight number (in thousands) WHO | WHO | −0.9% |
| Low birth weight prevalence (%) WHO | WHO | −1.3% |
| Underweight among adults, BMI < 18.5 kg/m2 (age-standardized estimate) (%) WHO | WHO | 0% |
| Underweight among adults, BMI < 18.5 kg/m2 (crude estimate) (%) WHO | WHO | 0% |
| Overweight among adults, BMI ≥ 25 kg/m2 (age-standardized estimate) (%) WHO | WHO | +1.6% |
| Overweight among adults, BMI ≥ 25 kg/m2 (crude estimate) (%) WHO | WHO | +1.4% |
| Obesity among adults, BMI ≥ 30 kg/m2 (age-standardized estimate) (%) WHO | WHO | +3.1% |
| Obesity among adults, BMI ≥ 30 kg/m2 (crude estimate) (%) WHO | WHO | +3.1% |
| Proportion of population with primary reliance on clean fuels and technologies for cooking (%) WHO | WHO | +1.1% |
| Births attended by skilled health personnel (%) WHO | WHO | −1.1% |
| Current health expenditure (CHE) per capita in US$ WHO | WHO | +0.1% |
| Current health expenditure (CHE) as percentage of gross domestic product (GDP) (%) WHO | WHO | −7.5% |
| External health expenditure (EXT) per capita in US$ WHO | WHO | 0% |
| External health expenditure (EXT) as percentage of current health expenditure (CHE) (%) WHO | WHO | 0 |
| Domestic general government health expenditure (GGHE-D) per capita in US$ WHO | WHO | −0.8% |
| Domestic general government health expenditure (GGHE-D) as percentage of current health expenditure (CHE) (%) WHO | WHO | −0.9% |
| Domestic general government health expenditure (GGHE-D) as percentage of gross domestic product (GDP) (%) WHO | WHO | −8.4% |
| Domestic general government health expenditure (GGHE-D) as percentage of general government expenditure (GGE) (%) WHO | WHO | −4.3% |
| Out-of-pocket expenditure (OOP) per capita in US$ WHO | WHO | −0.1% |
| Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%) WHO | WHO | −0.2% |
| Domestic private health expenditure (PVT-D) per capita in US$ WHO | WHO | +1.7% |
| Domestic private health expenditure (PVT-D) as percentage of current health expenditure (CHE) (%) WHO | WHO | +1.6% |
| Adolescent birth rate (per 1000 women) WHO | WHO | −16.7% |
| Medical doctors (per 10,000) WHO | WHO | +2.4% |
| Nursing and midwifery personnel (per 10,000) WHO | WHO | +1.4% |
| Dentists (per 10,000) WHO | WHO | +1.9% |
| Pharmacists (per 10,000) WHO | WHO | +7.8% |
| Reported number of people requiring interventions against NTDs WHO | WHO | 0% |
| Tobacco MPOWER Protect people: P2 smoke-free places, additional characteristics WHO | WHO | 0 |
| Tobacco Monitor: school-based national surveys, tobacco use, tobacco smoking, and cigarette smoking, prevalence WHO | WHO | – |
| Tobacco Monitor: school-based national surveys, smokeless tobacco or e-cigarettes, prevalence WHO | WHO | – |
| Tobacco Monitor: population-based national surveys, tobacco use and smoking, prevalence WHO | WHO | – |
| Best-practice policy implemented for industrially produced trans-fatty acids (TFA) (Y/N) WHO | WHO | 0% |
| Tobacco Monitor: population-based national surveys, tobacco use and smoking WHO | WHO | – |
| Tobacco Monitor: school-based national surveys, tobacco use and smoking WHO | WHO | – |
| Tobacco Monitor: school-based national surveys, smokeless tobacco or e-cigarettes WHO | WHO | – |
| Environmental and Occupational Health and Hygiene Professionals (number) WHO | WHO | +31.4% |
| Environmental and Occupational Health Inspectors and Associates (number) WHO | WHO | −12.2% |
| Medical and Pathology Laboratory scientists (number) WHO | WHO | +34.8% |
| Medical and Pathology Laboratory Technicians (number) WHO | WHO | 0% |
| Physiotherapists (number) WHO | WHO | +11% |
| Physiotherapy Technicians and Assistants (number) WHO | WHO | −2.4% |
| Traditional and Complementary Medicine Professionals (number) WHO | WHO | – |
| Pharmacists (number) WHO | WHO | +9.1% |
| Pharmaceutical Technicians and Assistants (number) WHO | WHO | +5.4% |
| Dentists (number) WHO | WHO | +3% |
| Dental Assistants and Therapists (number) WHO | WHO | −47% |
| Dental Prosthetic Technicians (number) WHO | WHO | 0% |
| Nursing and midwifery personnel (number) WHO | WHO | +2.5% |
| Nursing personnel (number) WHO | WHO | +2.2% |
| Midwifery personnel (number) WHO | WHO | +3.3% |
| Nursing personnel (%) WHO | WHO | 0% |
| Medical doctors (number) WHO | WHO | +3.5% |
| Generalist medical practitioners (number) WHO | WHO | +5.4% |
| Specialist medical practitioners (number) WHO | WHO | +1.2% |
| Medical doctors not further defined (number) WHO | WHO | +7.3% |
| Medical doctors (%) WHO | WHO | +63.8% |
| Estimate of current cigarette smoking prevalence (%) (age-standardized) WHO | WHO | −8.7% |
| Number of current cigarette smokers, estimate WHO | WHO | −3% |
| Estimate of current tobacco smoking prevalence (%) (age-standardized rate) WHO | WHO | −3.7% |
| Estimate of current tobacco use prevalence (%) (age-standardized) WHO | WHO | −4% |
| Estimate of current cigarette smoking prevalence (%) WHO | WHO | −8.7% |
| Estimate of current tobacco smoking prevalence (%) WHO | WHO | −3.7% |
| Antenatal care attendees who were positive for syphilis (%), reported WHO | WHO | +8.6% |
| Antimicrobial resistance or decreased susceptibiity (DS/R) to antimicrobials in Neisseria gonorrhoea isolates (WHO-GASP) (proportion) WHO | WHO | +322.6% |
| Antimicrobial resistance or decreased susceptibiity (DS/R) to antimicrobials testing in Neisseria gonorrhoea isolates (WHO-GASP) (number) WHO | WHO | +90.6% |
| Total number of malaria cases (presumed + confirmed cases) WHO | WHO | +50.3% |
| Number of suspected malaria cases WHO | WHO | −41.7% |
| Number of malaria suspects examined by rapid diagnostic test (RDT) WHO | WHO | +564.5% |
| Number of malaria positive cases by rapid diagnostic test (RDT) WHO | WHO | +69.2% |
| Number of indigenous P. vivax malaria cases WHO | WHO | +45.5% |
| Number of presumed malaria cases WHO | WHO | 0 |
| Number of indigenous P. falciparum malaria cases WHO | WHO | +76.3% |
| Domestic Expenditure on Malaria WHO | WHO | +31% |
| Number of malaria suspects examined by microscopy WHO | WHO | −44.3% |
| Number of malaria positive cases by microscopy WHO | WHO | −51% |
| Number of people protected from malaria by indoor residual spraying (IRS) WHO | WHO | −5% |
| Number of indigenous malaria cases WHO | WHO | +49.9% |
| Number of imported malaria cases WHO | WHO | +827.3% |
| Number of confirmed malaria cases WHO | WHO | +50.3% |
| Number of malaria cases treated with artemisinin-based combination therapies (ACTs) WHO | WHO | +16% |
| Number of malaria cases treated with any first line tx courses (including artemisinin-based combination therapies (ACTs)) WHO | WHO | +46.9% |
| Estimated malaria mortality rate (per 100 000 population) WHO | WHO | +66.7% |
| Estimated malaria incidence (per 1000 population at risk) WHO | WHO | +48.4% |
| Estimated number of malaria deaths WHO | WHO | +65% |
| Estimated number of malaria cases WHO | WHO | +49.9% |
| Alcohol content in beverage in percent of volume, (alcohol by volume) (ABV %) WHO | WHO | −10.7% |
| Sugar-content of beverage (g/100ml) WHO | WHO | 0% |
| Primary data availability for UHC Service Coverage Index (SDG 3.8.1) (%) WHO | WHO | – |
| UHC Service Coverage Index (SDG 3.8.1) WHO | WHO | −1.4% |
| UHC Service Coverage sub-index on service capacity and access WHO | WHO | −7.6% |
| UHC Service Coverage sub-index on infectious diseases WHO | WHO | 0% |
| UHC Service Coverage sub-index on noncommunicable diseases WHO | WHO | 0% |
| UHC Service Coverage sub-index on reproductive, maternal, newborn and child health WHO | WHO | 0% |
| Treatment success rate: XDR-TB cases WHO | WHO | −16.7% |
| HIV-positive TB patients on ART (antiretroviral therapy) (%) WHO | WHO | +1.8% |
| TB patients with known HIV status (%) WHO | WHO | +2.1% |
| Tested TB patients HIV-positive (%) WHO | WHO | −8.3% |
| Treatment success rate for patients treated for MDR-TB (%) WHO | WHO | −10.9% |
| Treatment success rate: new TB cases WHO | WHO | +1.2% |
| Treatment success rate: previously treated TB cases WHO | WHO | −7.3% |
| Treatment success rate: HIV-positive TB cases WHO | WHO | +1.6% |